NEW YORK, Feb. 23, 2017 /PRNewswire/ -- Provides
understanding and access to the acute and chronic myelogenous
leukemia partnering deals and agreements entered into by the worlds
leading healthcare companies.
Read the full report:
http://www.reportlinker.com/p03605667-summary/view-report.html
Description
The Global Acute and Chronic Myelogenous Leukemia Partnering Terms
and Agreements since 2010 report provides understanding and access
to partnering deals and agreements entered into by the world's
leading healthcare companies.
- Trends in partnering deals
- Top deals by value
- Deals listed by company A-Z, industry sector, stage of
development, technology type
The report provides understanding and access to the partnering
deals and agreements entered into by the world's leading healthcare
companies.
The report provides an analysis of partnering deals. The
majority of deals are discovery or development stage whereby the
licensee obtains a right or an option right to license the
licensors technology. These deals tend to be multicomponent,
starting with collaborative R&D, and commercialization of
outcomes.
Understanding the flexibility of a prospective partner's
negotiated deals terms provides critical insight into the
negotiation process in terms of what you can expect to achieve
during the negotiation of terms. Whilst many smaller companies will
be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered – contract documents
provide this insight where press releases do not.
This data driven report contains multiple links to online copies
of actual deals and contract documents as submitted to the
Securities Exchange Commission by companies and their partners,
where available. Contract documents provide the answers to numerous
questions about a prospective partner's flexibility on a wide range
of important issues, many of which will have a significant impact
on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of
partnering trends.
Chapter 1 provides an overview of the trends in partnering since
2010, including a summary of deals by industry sector, stage of
development, deal type, and technology type.
Chapter 2 provides a review of the top 10 most active companies in
the therapy area, including a comprehensive listing of the deals
announced by each company.
Chapter 3 provides a comprehensive directory of partnering deals
signed and announced since 2010. The chapter is organized by
company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc), and
technology type. Each deal title links via Weblink to an online
version of the deal record, and where available the contract
document, providing easy access to each contract document on
demand.
Chapter 4 provides a listing of partnering deals where a contract
document is available alongside the deal record.
Chapters 5 and 6 provide a summary of M&A deals since 2010
where the acquired company is active in the therapy area of
interest.
Chapters 7 and 8 provide a summary of financings since 2010 where
the financed company is active in the therapy area of interest.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research,
development and commercialization of technologies and products in
the therapy area.
Read the full report:
http://www.reportlinker.com/p03605667-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/global-acute-and-chronic-myelogenous-leukemia-partnering-2010-to-2017-300413125.html
SOURCE Reportlinker